Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study
Open accessThe DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Introduction: Pulmonary involvement represents a major cause of death of systemic sclerosis (SSc) patients. Recent data suggest that tyrosine kinase inhibitors, such as imatinib, may be a therapeutic option for SSc patients. However, preliminary published clinical trials were inconclusive about imatinib efficacy and showed side effects. The purpose of this study was to verify efficacy and tolerability of low-dose imatinib on interstitial lung disease in a cohort of SSc patients unresponsive to cyclophosphamide therapy. Methods: Thirty consecutive SSc patients with active pulmonary involvement, unresponsive to cyclophosphamide, were treated with imatinib 200 mg/day for 6 months followed by a 6-month follow-up. A “good response” was defined as an increase of forced vital capacity (FVC) by more of 15% and/or increase of diffusing capacity of carbon monoxide (DL CO) >15% and PaO 2 > 90% of initial value and high-resolution computed tomography (HRCT)-scan pattern unchanged or improved. Results: Twenty-six patients completed the study. Three patients died and one patient was lost to follow-up. Four patients (15.32%) had a good response, 7 worsened and 15 had a stabilized lung disease. Overall, 19 (73.07%) patients had an improved or stabilized lung disease. After a 6-month follow-up, 12 (54.5%) of the 22 patients showed an improved or stabilized lung disease. Conclusions: Lung function was stabilized in a large proportion of patients unresponsive to cyclophosphamide therapy and a beneficial outcome emerged from the analysis of HRCT lung scans. There was no significant improvement of skin involvement, and the low dose was well tolerated. These data provide useful suggestions to design future randomized clinical trials for SSc therapeutics. Trial registration: ClinicalTrials.gov NCT00573326. Registered 13 December 2007.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A low dose of imatinib has also been tested in an open label study for treatment of intestitial lung disease in SSc patients unresponsive to cyclophosphamide (184), and was reported to stabilize lung function but again had no effect on skin.”
From Unraveling SSc Pathophysiology; The Myofibroblast (2018) · cites this paper as [184]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preliminary criteria for the classification of systemic sclerosis (scleroderma)
Masi, A. T., & Subcommittee For Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) · Arthritis & Rheumatism · doi:10.1002/art.1780230510 · Cited by 4,898
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636 · cited 2×
“In view of these discordant data, we designed a multicenter, prospective, open-label trial with the following characteristics: only SSc patients with active lung involvement, despite previous therapy with cyclophosphamide, were enrolled; a single dose of 200 mg/day imatinib mesylate was used; the study was structured…”
MethodInfluentialStandardisation of the measurement of lung volumes
Wanger, J., Clausen, J. L., Coates, A., Pedersen, O. F., Brusasco, V., Burgos, F., Casaburi, R., Crapo, R., Enright, P., van der Grinten, C. P. M., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00035005 · Cited by 2,768 · cited 1×
“Pulmonary function tests and single-breath diffusing capacity were performed in accordance with recommended standards [20,21].”
MethodStandardisation of the single-breath determination of carbon monoxide uptake in the lung
MacIntyre, N., Crapo, R. O., Viegi, G., Johnson, D. C., van der Grinten, C. P. M., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Enright, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034905 · Cited by 2,255
Cyclophosphamide versus placebo in scleroderma lung disease
Tashkin, D. P., Elashoff, R., Clements, P. J., Goldin, J., Roth, M. D., Furst, D. E., Arriola, E., Silver, R., Strange, C., Bolster, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055120 · Cited by 1,677
Changes in causes of death in systemic sclerosis, 1972–2002
Steen, V. D., & Medsger, T. A. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.066068 · Cited by 1,528 · cited 2×
“75 to 62) years and median disease duration (defined as the time from the onset of the first non-Raynaud’s phenomenon clinical manifestation) was 3 years [1-6].”
BackgroundGlivec (STI571, imatinib), a rationally developed, targeted anticancer drug
Capdeville, R., Buchdunger, E., Zimmermann, J., & Matter, A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd839 · Cited by 1,389 · cited 1×
“Imatinib mesylate (Gleevec; Novartis Europharm Ltd, Wimblehurst Road, Horsham, West Sussex RH12 4AB, UK) has been approved for the therapy of chronic myelogenous leukemia and gastrointestinal stromal tumors [7].”
BackgroundGabrielli, A., Avvedimento, E. V., & Krieg, T. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0806188 · Cited by 1,384
Self-citationMahler, D. A., Weinberg, D. H., Wells, C. K., & Feinstein, A. R. (1984) · Chest · doi:10.1378/chest.85.6.751 · Cited by 1,292 · cited 2×
“The diagnosis of active lung involvement required the presence of grade 2 exertional dyspnea according to the Mahler Baseline Dyspnea Index [19] plus interstitial alveolitis assessed by high-resolution computed tomography (HRCT) scan (ground-glass opacifications involving at least two lung segments) or neutrophilic (>3”
MethodClements, P. J., Lachenbruch, P. A., Siebold, J., White, B., Weiner, S. J., Martin, R. W., Weinstein, A., Weisman, M. H., Mayes, M. D., & Collier, D. H. (1995) · PubMed · Cited by 874
Research works printed but not linked: 1
- Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliand DG, Druker BJ: CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood. 1997, 15: 4947-4952. · DOI · Paper page
Cited by
Spagnolo, P., Distler, O., Ryerson, C. J., Tzouvelekis, A., Lee, J. S., Bonella, F., Bouros, D., Hoffmann-Vold, A.-M., Crestani, B., & Matteson, E. L. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217230 · Cited by 259
“34 Imatinib also inhibits the platelet-derived growth factor (PDGF) receptor tyrosine kinase and has been evaluated in small open-label studies in SSc-ILD, 35 36 although no large randomised trials have been conducted and its efficacy is unclear.”
MethodKlinkhammer, B. M., Floege, J., & Boor, P. (2018) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.11.008 · Cited by 229
“A third trial in scleroderma using 200 mg/day imatinib for six months found a stabilized lung function and good drug tolerance but no significant improvement of skin involvement (Fraticelli et al., 2014).”
BackgroundThe Role of Myofibroblasts in Physiological and Pathological Tissue Repair
Schuster, R., Younesi, F., Ezzo, M., & Hinz, B. (2023) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a041231 · Cited by 232
The evolving relationship of wound healing and tumor stroma
Foster, D. S., Jones, R. E., Ransom, R. C., Longaker, M. T., & Norton, J. A. (2018) · JCI Insight · doi:10.1172/jci.insight.99911 · Cited by 223
Systemic sclerosis: An update in 2016
Desbois, A. C., & Cacoub, P. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.01.007 · Cited by 175
“It showed an improvement or stabilization of lung disease in 15% and 58% of patients, respectively [96].”
Unraveling SSc Pathophysiology; The Myofibroblast
van Caam, A., Vonk, M., van den Hoogen, F., van Lent, P., & van der Kraan, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02452 · Cited by 153
Interstitial lung disease in systemic sclerosis: where do we stand?
Cappelli, S., Bellando-Randone, S., Camiciottoli, G., de Paulis, A., Guiducci, S., & Matucci‐Cerinic, M. (2015) · European Respiratory Review · doi:10.1183/16000617.00002915 · Cited by 114
Current perspectives on the immunopathogenesis of systemic sclerosis
Fuschiotti, P. (2016) · ImmunoTargets and Therapy · doi:10.2147/itt.s82037 · Cited by 110
“In a recent study, low-dose imatinib was used in a cohort of patients with SSc-ILD with active pulmonary disease and unresponsive to cyclophosphamide.(182) Of note, 73% of the 30 patients treated had improved or stabilized”
Interstitial lung disease in systemic sclerosis: current and future treatment
Giacomelli, R., Liakouli, V., Berardicurti, O., Ruscitti, P., Benedetto, P. D., Carubbi, F., Guggino, G., Bartolomeo, S. D., Ciccia, F., Triolo, G., et al. (2017) · Rheumatology International · doi:10.1007/s00296-016-3636-7 · Cited by 103
“The drug was well tolerated and stabilized the FVC in a large proportion of patients, improving the HRCT lung scans, thus suggesting the need of more extensive studies in SSc–ILD [82].”
Self-citationInterstitial lung disease in systemic autoimmune rheumatic diseases: a comprehensive review
Atzeni, F., Gerardi, M. C., Barilaro, G., Masala, I. F., Benucci, M., & Sarzi‐Puttini, P. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2018.1411190 · Cited by 101
“ILD, and an improvement in or stabilization of the lung disease was observed in, respectively, 15% and 58% [61].”
BackgroundGordon, J. K., Martyanov, V., Magro, C., Wildman, H. F., Wood, T. A., Huang, W.-T., Crow, M. K., Whitfield, M. L., & Spiera, R. F. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0721-3 · Cited by 92
What can target kidney fibrosis?
Leaf, I. A., & Duffield, J. S. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw388 · Cited by 94
Systemic Sclerosis Pathogenesis and Emerging Therapies, beyond the Fibroblast
Sierra-Sepúlveda, A., Esquinca-González, A., Benavides-Suárez, S. A., Sordo-Lima, D. E., Caballero-Islas, A. E., Cabral-Castañeda, A. R., & Rodríguez-Reyna, T. S. (2019) · BioMed Research International · doi:10.1155/2019/4569826 · Cited by 103
Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease
Caron, M., Hoa, S. A.-T., Hudson, M., Schwartzman, K., & Steele, R. J. (2018) · European Respiratory Review · doi:10.1183/16000617.0102-2017 · Cited by 89
“2014[116] Italy Experimental Study 30 (70% Female) 51 (41.”
Volkmann, E. R., & Tashkin, D. P. (2016) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201606-426fr · Cited by 110
Condorelli, A. G., Hachem, M. E., Zambruno, G., Nyström, A., Candi, E., & Castiglia, D. (2021) · Journal of Biomedical Science · doi:10.1186/s12929-021-00732-8 · Cited by 79
pDCs in lung and skin fibrosis in a bleomycin-induced model and patients with systemic sclerosis
Kafaja, S., Valera, I., Divekar, A., Saggar, R., Abtin, F. G., Fürst, D. E., Khanna, D., & Singh, R. R. (2018) · JCI Insight · doi:10.1172/jci.insight.98380 · Cited by 75
“BAL pDCs correlated with GGO, which represents earlier stages of SSc-ILD (22, 23), and negatively correlated with disease duration.”
BackgroundInfluentialPulmonary involvement in systemic sclerosis
Morales-Cárdenas, A., Madrid, C. P., Arias, L., Ojeda, P., Mahecha, M. P., Rojas‐Villarraga, A., Carrillo-Bayona, J. A., & Anaya, J. (2016) · Autoimmunity Reviews · doi:10.1016/j.autrev.2016.07.025 · Cited by 70
Vacchi, C., Sebastiani, M., Cassone, G., Cerri, S., Casa, G. D., Salvarani, C., & Manfredi, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020407 · Cited by 74
“Imatinib did not demonstrate efficacy in SSc-ILD and in general was not well tolerated [22,23].”
BackgroundMethodSystemic sclerosis: Current concepts of skin and systemic manifestations
Pearson, D. R., Werth, V. P., & Pappas‐Taffer, L. (2018) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2018.04.004 · Cited by 74
Involvement of the myeloid cell compartment in fibrogenesis and systemic sclerosis
Kania, G., Rudnik, M., & Distler, O. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0212-z · Cited by 71
Codullo, V., Cova, E., Pandolfi, L., Breda, S., Morosini, M., Frangipane, V., Malatesta, M., Calderan, L., Cagnone, M., Pacini, C., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.08.015 · Cited by 61
Diagnostic criteria, severity classification and guidelines of systemic sclerosis
Asano, Y., Jinnin, M., Kawaguchi, Y., Kuwana, M., Goto, D., Sato, S., Takehara, K., Hatano, M., Fujimoto, M., Mugii, N., et al. (2018) · The Journal of Dermatology · doi:10.1111/1346-8138.14162 · Cited by 68
Interstitial Lung Disease in Systemic Sclerosis: Focus on Early Detection and Intervention
Fischer, A., Patel, N. M., & Volkmann, E. R. (2019) · Open Access Rheumatology Research and Reviews · doi:10.2147/oarrr.s226695 · Cited by 61
“A subsequent phase II pilot study reported that imatinib 200 mg/day stabilized lung function and improved HRCT scan patterns in patients with SSc-ILD who were unresponsive to CYC (NCT00573326).(130) Dasatinib and nilotinib are examples of second-generation TKIs; these compounds block several receptor and non-receptor…”
BackgroundPDGF/PDGFR: A Possible Molecular Target in Scleroderma Fibrosis
Paolini, C., Agarbati, S., Benfaremo, D., Mozzicafreddo, M., Svegliati, S., & Moroncini, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073904 · Cited by 55
“Subsequent randomized and controlled trials yielded mostly negative results, reporting that imatinib use was not associated with improvement of cutaneous involvement, although it may determine the stabilization of lung function [65,69].”
BackgroundSelf-citationYao, F., Luo, Y., Liu, Y.-C., Chen, Y., Li, Y.-T., Hu, X., You, X., Yu, S., Li, Z., Chen, L., et al. (2022) · Inflammation and Regeneration · doi:10.1186/s41232-022-00223-9 · Cited by 52
Luchetti, M. M., Moroncini, G., Escamez, M. J., Svegliati, S., Spadoni, T., Grieco, A., Paolini, C., Funaro, A., Avvedimento, E. V., Larcher, F., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39728 · Cited by 53
Self-citationPark, J.-S., Oh, Y., Park, Y. J., Park, O., Yang, H. S., Slania, S., Hummers, L. K., Shah, A. A., An, H.-T., Jang, J., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09101-4 · Cited by 52
Moroncini, G., Paolini, C., Orlando, F., Capelli, C., Grieco, A., Tonnini, C., Agarbati, S., Mondini, E., Saccomanno, S., Goteri, G., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0196048 · Cited by 52
“Imatinib was tested in a prospective, phase II pilot study that included 30 SSc patients with active ILD, unresponsive to CYC, and resulted in an improvement or stabilization of lung disease in about 70% of patients[12].”
MethodSelf-citationJee, A. S., & Corte, T. J. (2019) · Drugs · doi:10.1007/s40265-019-01178-x · Cited by 51
Targeting TLRs and the inflammasome in systemic sclerosis
Henderson, J., Bhattacharyya, S., Varga, J., & O’Reilly, S. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.003 · Cited by 46
Strategy for treatment of fibrosis in systemic sclerosis: Present and future
Yanaba, K. (2016) · The Journal of Dermatology · doi:10.1111/1346-8138.13026 · Cited by 43
Novel insights into dendritic cells in the pathogenesis of systemic sclerosis
Carvalheiro, T., Zimmermann, M., Radstake, T. R. D. J., & Marut, W. (2020) · Clinical and Experimental Immunology · doi:10.1111/cei.13417 · Cited by 40
“Furthermore, imatinib treatment in SSc patients reduced pDCs number in the lung and improved skin and lung disease (43, 44).”
BackgroundSystemic Sclerosis: From Pathophysiology to Novel Therapeutic Approaches
Benfaremo, D., Svegliati, S., Paolini, C., Agarbati, S., & Moroncini, G. (2022) · Biomedicines · doi:10.3390/biomedicines10010163 · Cited by 45
Self-citationSvegliati, S., Amico, D., Spadoni, T., Fischetti, C., Finke, D., Moroncini, G., Paolini, C., Tonnini, C., Grieco, A., Rovinelli, M., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00075 · Cited by 43
Self-citationDantas, A. T., Gonçalves, S. M. C., de Almeida, A. R., Gonçalves, R. S. G., Sampaio, M. C. P. D., Vilar, K. D. M., Pereira, M. C., Rêgo, M. J. B. D. M., Pitta, I. D. R., Marques, C. D. L., et al. (2016) · Disease Markers · doi:10.1155/2016/6064830 · Cited by 35
Pharmacological treatments for SSc-ILD: Systematic review and critical appraisal of the evidence
Vonk, M. C., Smith, V. M., Sfikakis, P. P., Cutolo, M., Galdo, F. D., & Seibold, J. R. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102978 · Cited by 35
“0002), but not in the number of lung segments with honeycombing [81].”
BackgroundInfluentialYoung, A., & Khanna, D. (2015) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000172 · Cited by 33
Systemic sclerosis: a critical digest of the recent literature.
Tani, C., Randone, S. B., Guiducci, S., & Rossa, A. D. (2013) · PubMed · Cited by 34
Use of biologics and other novel therapies for the treatment of systemic sclerosis
Bruni, C., Praino, E., Allanore, Y., Distler, O., Gabrielli, A., Iannone, F., & Matucci‐Cerinic, M. (2016) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1263153 · Cited by 31
Self-citationPapadimitriou, T. I., van Caam, A., van der Kraan, P. M., & Thurlings, R. M. (2022) · Biomedicines · doi:10.3390/biomedicines10020316 · Cited by 34
“From a mechanistic point of view, imatinib successfully depleted patients’ pDCs, immune cells that play an important role in the disease’s pathogenesis [192,193].”
BackgroundIudici, M., Moroncini, G., Cipriani, P., Giacomelli, R., Gabrielli, A., & Valentini, G. (2015) · Autoimmunity Reviews · doi:10.1016/j.autrev.2015.02.002 · Cited by 30
“Imatinib was tested in a prospective, 6-month, low-dose (200 mg/day), phase II study that included 30 SSc patients with active ILD, unresponsive to CYC [52], and resulted in an improvement or stabilization of lung disease in about 70% of patients.”
Self-citationSystemic Sclerosis Associated Interstitial Lung Disease: New Directions in Disease Management
Mirsaeidi, M. S., Barletta, P., & Glassberg, M. K. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00248 · Cited by 33
Saketkoo, L. A., Scholand, M. B., Lammi, M. R., & Russell, A. (2020) · Journal of Scleroderma and Related Disorders · doi:10.1177/2397198320904178 · Cited by 29
Mendoza, F. A., Piera-Velázquez, S., & Jiménez, S. A. (2021) · Translational research · doi:10.1016/j.trsl.2021.01.001 · Cited by 29
Petelytska, L., Bonomi, F., Cannistrà, C., Fiorentini, E., Peretti, S., Torracchi, S., Bernardini, P., Coccia, C., Luca, R. D., Economou, A., et al. (2023) · RMD Open · doi:10.1136/rmdopen-2023-003426 · Cited by 27
Pharmacological management of Idiopathic Pulmonary Fibrosis: current and emerging options
Trachalaki, A., Irfan, M., & Wells, A. U. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1822326 · Cited by 26
KIT as a therapeutic target for non-oncological diseases
Martínez‐Antón, A., Gras, D., BOURDIN, A. A., Dubreuil, P. C., & Chanez, P. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.12.008 · Cited by 24
Systemic Sclerosis Associated Interstitial Lung Disease: A Comprehensive Overview
Mackintosh, J. A., Stainer, A., Barnett, J. L., & Renzoni, E. A. (2019) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0039-1683431 · Cited by 25
Benedetto, P. D., Ruscitti, P., Liakouli, V., Galdo, F. D., Giacomelli, R., & Cipriani, P. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10429 · Cited by 28
“FPDs are able to cause significant morbidity and mortality in affected patients (1,2,78), thus the development of novel therapies are still required (79-81).”
Self-citationThe future of treatment in systemic sclerosis: can we design better trials?
Pope, J. E. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30010-2 · Cited by 21
Haddon, D. J., Wand, H., Jarrell, J. A., Spiera, R., Utz, P. J., Gordon, J., & Chung, L. S. (2017) · The Journal of Rheumatology · doi:10.3899/jrheum.160833 · Cited by 20
Recent Treatments of Interstitial Lung Disease with Systemic Sclerosis
Yasuoka, H. (2015) · Clinical Medicine Insights Circulatory Respiratory and Pulmonary Medicine · doi:10.4137/ccrpm.s23315 · Cited by 19
What should clinicians know about the use of glucocorticoids in systemic sclerosis?
Iudici, M. (2017) · Modern Rheumatology · doi:10.1080/14397595.2016.1270796 · Cited by 17
The Laboratory Diagnosis of the Antiphospholipid Syndrome
Ahluwalia, J., & Sreedharanunni, S. (2016) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-016-0739-y · Cited by 18
Karakontaki, F., Panselinas, E., Polychronopoulos, V., & Tzioufas, A. G. (2020) · Autoimmunity Reviews · doi:10.1016/j.autrev.2020.102742 · Cited by 14
Liakouli, V., Ciaffi, J., Ursini, F., Ruscitti, P., Melicòni, R., Ciccia, F., Cipriani, P., & Giacomelli, R. (2020) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2020.1813569 · Cited by 12
Self-citationMcCray, C. J., & Mayes, M. D. (2015) · Current Allergy and Asthma Reports · doi:10.1007/s11882-015-0526-0 · Cited by 12
Roofeh, D., Barratt, S. L., Wells, A. U., Kawano-Dourado, L. B., Tashkin, D. P., Strand, V., Seibold, J. R., Proudman, S., Brown, K. K., Dellaripa, P. F., et al. (2021) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2021.08.001 · Cited by 11
Systemic sclerosis: Update for oral health care providers
Alhendi, F., Werth, V. P., Sollecito, T. P., & Stoopler, E. T. (2020) · Special Care in Dentistry · doi:10.1111/scd.12492 · Cited by 11
Mastocytosis and systemic sclerosis: a clinical association
Bagnato, G., Roberts, W. N., Sciortino, D., Sangari, D., Cirmi, S., Ravenell, R. L., Navarra, M., Bagnato, G., & Gangemi, S. (2016) · Clinical and Molecular Allergy · doi:10.1186/s12948-016-0050-3 · Cited by 9
“Promising results have been reported in animal models [23] and in clinical trials related to skin fibrosis and lung function [24].”
ResultInterstitial lung disease in Systemic sclerosis: insights into pathogenesis and evolving therapies
Ahmed, S., Pattanaik, S. S., Rai, M. K., Nath, A., & Agarwal, V. (2018) · Mediterranean Journal of Rheumatology · doi:10.31138/mjr.29.3.140 · Cited by 9
Huang, X., Khoong, Y., Han, C., Su, D., Ma, H., Gu, S., Li, Q., & Zan, T. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.694605 · Cited by 9
Perspective to precision medicine in scleroderma
Komura, K., Yanaba, K., Bouaziz, J., Yoshizaki, A., Hasegawa, M., Varga, J., Takehara, K., & Matsushita, T. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1298665 · Cited by 9
Bing, H., Gao, S., Sang, Y., Wang, L., Meng, X., & You, J.-Y. (2019) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b1900205 · Cited by 8
Cheng, X., Li, K., Liu, J., Wang, Q., Zhang, Z., Zhang, L., Xie, Y., Chang, L., Zeng, D., Tian, L., et al. (2025) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2025.100991 · Cited by 7
“At present, positive therapeutic effects of certain small-molecule inhibitors have been observed in preclinical animal models of liver fi brosis and in patients with liver fi brosis (63, 64).”
Papa, N. D., & Zaccara, E. (2015) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2016.02.004 · Cited by 9
Antifibrotics in systemic sclerosis
Martín-López, M., & Carreira, P. E. (2021) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2021.101671 · Cited by 7
Mehrabi, S., Moradi, M. M., Khodamoradi, Z., & Nazarinia, M. A. (2019) · Current Rheumatology Reviews · doi:10.2174/1573397115666191212092608 · Cited by 7
Bagheri, L., Javanbakht, M., Malekian, S., Ghahderijani, B. H., Taghipour, S., Tanha, F. D., Ranjkesh, M. H., Cegolon, L., & Zhao, S. G. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177607 · Cited by 5
Fallet, B., & Walker, U. A. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1832466 · Cited by 5
“In a case series of five patients with SSc-ILD, pirfenidone improved the FVC in all patients [100].”
BackgroundUse of Patterned Collagen Coated Slides to Study Normal and Scleroderma Lung Fibroblast Migration
Abdi, B. A., Lopez, H., Karrar, S., Renzoni, E. A., Wells, A. U., Tam, A. Y. Y., Etomi, O. T., Hsuan, J. J., Martin, G. R., Shiwen, X., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-02621-3 · Cited by 5
Prêle, C. M., Braack, K. J., Atlas, M. D., Kuthubutheen, J., Miles, T., Mulders, W. H. A. M., & Mutsaers, S. E. (2025) · Cells · doi:10.3390/cells14231924 · Cited by 4
“However, results from these trials were highly variable, with an improvement in lung function and reduction in skin fibrosis in some patients with SSc [188,189] but no significant impact in IPF [190].”
Dumont, A., Dolladille, C., de BOYSSON, H., Alexandre, J., Nguyen, A., Deshayes, S., & Aouba, A. (2022) · Autoimmunity Reviews · doi:10.1016/j.autrev.2022.103157 · Cited by 5
Ferrari, H. M., Kale-Pradhan, P. B., Konja, J., Dierker, M. S., & Martirosov, A. L. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231213672 · Cited by 4
Treatment of Scleroderma with Para-Aminobenzoic Acid: Effect on Disease Morbidity.
Sawalha, K. (2018) · Archives of General Internal Medicine · doi:10.4066/2591-7951.1000052 · Cited by 4
“[27] There is no strong evidence of its efficacy on skin fibrosis.”
BackgroundThe contemporary management of systemic sclerosis
Eldoma, M., & Pope, J. E. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2018.1485490 · Cited by 4
Gunes, I., Bernstein, E. J., Cowper, S. E., Panse, G., Pradhan, N., Camacho, L. D., Page, N., Bundschuh, E., Williams, A., Carns, M. A., et al. (2025) · Arthritis Research & Therapy · doi:10.1186/s13075-025-03508-9 · Cited by 3
Juvenile Localized and Systemic Scleroderma
Graham, L. V. D., Paller, A. S., & Foeldvari, I. (2016) · Springer eBooks · doi:10.1007/978-3-319-31407-5_7 · Cited by 3
Immunopathogenesis and Immune-based Therapy for Selected Autoimmune Disorders
Aribi, M. (2017) · InTech eBooks · doi:10.5772/63032 · Cited by 3
Englert, H., Richards, B., Angelides, S., Kumar, V., Spencer, D. G., Howe, G. B., & Manolios, N. (2021) · Annals of Nuclear Medicine · doi:10.1007/s12149-021-01653-0 · Cited by 3
Mikhaylova, I. N., Treshalina, N. M., Shubina, I. Z., Владимировна, М. И., Kiselevsky, M. V., & Lukashev, A. N. (2021) · Advances in molecular oncology · doi:10.17650/2313-805x-2020-7-4-20-28 · Cited by 2
“В другом исследовании у пациентов (n = 30) с активным пневмофиброзом, не отвечающим на циклофосфамид, 6-месячный курс иматиниба в суточной дозе 200 мг стабилизировал процесс [43].”
Systemische Sklerose: Was ist gesichert in der Therapie?
Becker, M. O. (2016) · Der Internist · doi:10.1007/s00108-016-0148-1 · Cited by 2
Orteu, C. H., & Denton, C. P. (2024) · Wiley eBooks · doi:10.1002/9781119709268.rook054 · Cited by 2
Kersten, B. E., & Vonk, M. C. (2019) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-019-00119-9 · Cited by 2
Mast cells in collagen diseases
Mikita, N., Inaba, Y., Yoshimasu, T., Kanazawa, N., & Furukawa, F. (2017) · Trends in Immunotherapy · doi:10.24294/ti.v1.i2.96 · Cited by 1
Biologic Therapy in Inflammatory Immunomediated Systemic Diseases: Safety Profile
Moroncini, G., Albani, L., Nobili, L., & Gabrielli, A. (2015) · Current Drug Safety · doi:10.2174/1574886310666151014115251 · Cited by 1
Self-citationNigrovic, P. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-31696-5.00015-2 · Cited by 2
Allanore, Y. (2018) · Revue du Rhumatisme Monographies · doi:10.1016/j.monrhu.2018.02.003 · Cited by 1
Novel disease-modifying drugs against skin fibrosis of systemic sclerosis
Nishiguchi, M., Yamamoto, Y., & Jinnin, M. (2019) · Trends in Immunotherapy · doi:10.24294/ti.v2.i3.1050 · Cited by 1
Systemic Sclerosis (Systemic Scleroderma)
Orteu, C. H., & Denton, C. P. (2016) · Wiley eBooks · doi:10.1002/9781118441213.rtd0057 · Cited by 1
Sobre el tratamiento de la enfermedad pulmonar intersticial en artritis reumatoide
Ponce-Campos, S. D., Martín-Márquez, B. T., Chávez-García, D., Olvera-Palafox, C. N., Cardona‐Müller, D., Ponce-Muñoz, M., Díaz-Rizo, V., & González-López, L. (2015)
Transforming Growth Factor-ß and Connective Tissue Growth Factor
Fujimoto, M., & Takehara, K. (2016) · Springer eBooks · doi:10.1007/978-4-431-55708-1_9
Progressive Interstitial Lung Disease Nonresponse to Cyclophosphamide
Silver, K., Highland, K. B., & Silver, R. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-31407-5_55
Translating Autoimmune Pathogenesis into Targeted Therapies for Systemic Sclerosis
Russell, M., & Sofat, N. (2017) · InTech eBooks · doi:10.5772/66642
“More recently, a phase II open‐label study recruited 30 patients with active SSc‐ILD, unre‐ sponsive to cyclophosphamide, and administered a lower dose of 200 mg daily of imatinib for 6 months [49].”
BackgroundNovel approaches to identify biomechanisms in systemic sclerosis
Lopez, H. (2017) · UCL Discovery (University College London)
Systemic Sclerosis and Epigenetics
O’Reilly, S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809912-4.00010-6
Novel Disease-Modifying Drugs against Skin Fibrosis of Systemic Sclerosis
Nishiguchi, M., Yamamoto, Y., & Jinnin, M. (2020) · Trends in Immunotherapy · doi:10.24294/ti.v4.i2.1050
History and Scientific Production of Clinica Medica and Clinica Ematologica in Ancona
Gabrielli, A., Olivieri, A., Moroncini, G., Poloni, A., & Busilacchi, E. M. (2020) · Springer eBooks · doi:10.1007/978-3-030-33832-9_1
Self-citationAutoimmunity in interstitial lung disease
Sambataro, G., Sambataro, D., Adiletta, V., & Leone, P. M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85415-3.00006-4
Metadata
- Authors
- Fraticelli, P., Gabrielli, B., Pomponio, G., Valentini, G., Bosello, S., Riboldi, P., Gerosa, M., Faggioli, P., Giacomelli, R., Del Papa, N., Gerli, R., Lunardi, C., Bombardieri, S., Malorni, W., Corvetta, A., Moroncini, G., & Gabrielli, A.
- Affiliations
- Azienda Ospedaliero-Universitaria delle Marche (IT)
- University of Campania "Luigi Vanvitelli" (IT)
- Università Cattolica del Sacro Cuore (IT)
- University of Milan (IT)
- Azienda Ospedaliera Ospedale Civile di Legnano (IT)
- University of L'Aquila (IT)
- University of Perugia (IT)
- University of Verona (IT)
- University of Pisa (IT)
- Istituto Superiore di Sanità (IT)
- Ospedale Infermi di Rimini (IT)
- Marche Polytechnic University (IT)
- Corresponding author
- Gabrielli, Armando
- ORCID
- Venue
- Arthritis Research & Therapy
- Published
- 2014-07-08
- Volume
- 16
- Issue
- 4
- Pages
- R144-R144
- ISSN
- 1478-6354 (ISSN-L)
- PMC
- PMC4227120
- OpenAlex
- W2126719591
- Cited by
- 108
- References
- 33
- Citations by year
- 2025: 4 · 2024: 5 · 2023: 2 · 2022: 7 · 2021: 9 · 2020: 12 · 2019: 14 · 2018: 14 · 2017: 12 · 2016: 18 · 2015: 9
- FWCI
- 9.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Arthritis Research & Therapy (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi dell Aquila (submittedVersion, cc-by)
- Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Università Politecnica delle Marche (Università Politecnica delle Marche) (submittedVersion)
- PubliCatt (Università Cattolica del Sacro Cuore) (submittedVersion, other-oa)
- Funders
- Istituto Superiore di Sanità
- Università Cattolica del Sacro Cuore
- Istituto Auxologico Italiano
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Keywords
- systemic sclerosis, interstitial lung disease, imatinib, tyrosine kinase inhibitors, pulmonary involvement, lung function, forced vital capacity, diffusing capacity for carbon monoxide, high-resolution computed tomography, drug tolerability, skin involvement
- MeSH terms
- Imatinib Mesylate, Administration, Oral, Adult, Benzamides, Cyclophosphamide, Female, Humans, Immunosuppressive Agents, Male, Middle Aged, Pilot Projects, Piperazines, Pyrimidines, Respiratory Function Tests, Scleroderma, Systemic, Tomography, X-Ray Computed, Treatment Outcome, Lung Diseases, Interstitial, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.